Vibegron is an investigational oral beta-3 adrenergic receptor
agonist currently being assessed for the treatment of overactive bladder.
Developed by scientists at NTU, the new type of skin patch contains hundreds of micro-needles, each of them thinner than a human hair, which are loaded with the drug beta-3 adrenergic receptor agonist or another drug called triiodothyronine, containing thyroid hormone T3.
It contains a beta-3 adrenergic receptor agonist combined with hyaluronic acid, a substance naturally found in the human body and commonly used in products like skin moisturisers.
The first agent is mirabegron (Myrbetriq), which is the first FDA-approved beta-3 adrenergic receptor
Dow explains this is because they were developed before the human beta-3 adrenergic receptor
had been identified.
As outlined in this review, stepwise medical treatment for OAB is prudent and aimed at either competitively antagonizing the binding of acetylcholine to the muscarinic receptors (antimuscarinics), agonizing or stimulating the beta-3 adrenergic receptors
(mirabegron), or blocking the release of acetylcholine at the bladder neuromuscular junction (botulinum toxin).
Other drugs may act on other kinds of receptors involved in weight gain, such as the beta-3 adrenergic receptors
in fat tissue.